Press Release Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update 11 hours ago
Press Release Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 Aug 12
Press Release Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 Jul 30